Sanofi India Limited (SIL) declared its financial results for the quarter ended on March 31st, 2025. The Company has delivered net sales growth of 4% on a comparable basis of continuing business.

The successful launch of Soliqua, our best-in-class diabetes drug for the premix segment, continues with a steady growth reinstating confidence and strength in our comprehensive diabetes portfolio.

The company was able to increase its operating profit in Q1-2025 by 27% vs Q1-2024. The improved operating profit was a result of the Company’s focus mainly on lowering expenses through overall operating efficiencies.

The company continues to make good progress on its ‘India for India’ strategy through go-tomarket initiatives, improving operating efficiency and promoting innovation.

“The Company has delivered a strong first quarter performance reflecting Sanofi’s successful strategy for India. The Company will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its best-in-class innovative products in India,” Rachid Ayari, Whole Time Director and Chief Financial Officer, said.